| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |